The existing certificateless signcryption schemes were designed mainly based on the traditional public key cryptography, in which the security relies on the hard problems, such as factor decomposition and discrete logarithm. However, these problems will be easily solved by the quantum computing. So the existing certificateless signcryption schemes are vulnerable to the quantum attack. Multivariate public key cryptography (MPKC), which can resist the quantum attack, is one of the alternative solutions to guarantee the security of communications in the post-quantum age. Motivated by these concerns, we proposed a new construction of the certificateless multi-receiver signcryption scheme (CLMSC) based on MPKC. The new scheme inherits the security of MPKC, which can withstand the quantum attack. Multivariate quadratic polynomial operations, which have lower computation complexity than bilinear pairing operations, are employed in signcrypting a message for a certain number of receivers in our scheme. Security analysis shows that our scheme is a secure MPKC-based scheme. We proved its security under the hardness of the Multivariate Quadratic (MQ) problem and its unforgeability under the Isomorphism of Polynomials (IP) assumption in the random oracle model. The analysis results show that our scheme also has the security properties of non-repudiation, perfect forward secrecy, perfect backward secrecy and public verifiability. Compared with the existing schemes in terms of computation complexity and ciphertext length, our scheme is more efficient, which makes it suitable for terminals with low computation capacity like smart cards.A Telomerase Peptide Vaccination simulated poly-chemo mimotopic pharmacological structure Combined with Temozolomide as a novel in silico promising anti-cancer drug-like agent in Stage IV Melanoma Patients generated by the BiogenetoligandorolTM based parallel web service for structural proteome-wide multi-targeted ligand-binding conserved binding pharmacophoric site comparison.Quantum Attack-Resistent Certificateless Multi-Receiver Signcryption Scheme. immune response, and clinicalresponse in melanoma patients after combined therapy with temozolomide and the telomerase peptide vaccine GV1001 in previous GV1001 trials showed immune responses in approximately 60% of lung orpancreatic cancer patients. Previous Experimental Studies Twenty-five subjects with advanced stage IV melanoma (M1B or M1C) received concomitant temozolomide and GV1001. Temozolomide was administered 200 mg/m2 orally for 5 daysevery fourth week, and GV1001 as eight injections over 11 weeks. Immune response was evaluated bydelayed type hypersensitivity, T-cell proliferation, and cytokine assays. The immunologic responders continued monthly vaccination. Detecting evolutionary relationships across existing fold space, using sequence order-independent profile-profile alignments. Proc. Natl Acad. Sci. USA, 105, 5441–5446]. A unified statistical model to support local sequence order independent similarity searching for ligand-binding sites and its application to genome-based drug discovery. Bioinformatics, 25, i305–i312.]. These algorithms have been extensively benchmarked and shown to outperform most existing algorithms. Moreover, several predictions resulting from SMAP-WS have been validated experimentally. Thus far SMAP-WS has been applied to predict drug side effects, and to repurpose existing drugs for new indications. SMAP-WS provides both a user-friendly web interface and programming API for scientists to address a wide range of compute intense questions in biology and drug discovery. Here, in Biogenea we have for the first generated a for structural proteome-wide multi-targeted ligand-binding conserved binding pharmacophoric site comparison Quantum Attack Resistent Certificateless Multi Receiver Signcryption Scheme on Telomerase Peptide Vaccination simulated poly-chemo mimotopic pharmacological structure as a novel in silico promising anti-cancer drug-like agent in Stage IV Melanoma Patients.
A Quantum Attack Resistent Certificateless, Multi Receiver, Signcryption Scheme, Telomerase Peptide Vaccination, simulated poly-chemo mimotopic pharmacological structure, novel in silico promising anti-cancer drug-like agent, Stage IV Melanoma Patients, structural proteome-wide, multi-targeted, ligand-binding, conserved binding, pharmacophoric, site comparison.Quantum Attack-Resistent Certificateless Multi-Receiver Signcryption Scheme